Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
IPO Year: 2020
Exchange: NASDAQ
Website: kiromic.com
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
S-1/A - Kiromic Biopharma, Inc. (0001792581) (Filer)
10-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K/A - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
S-1 - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
10-Q - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13D - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13D/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13D - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13G - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13G - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13G - Kiromic Biopharma, Inc. (0001792581) (Subject)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports continued favorable efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical trial and provides an enrollment update. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic or locally-advanced non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. The fourth patient in Deltacel-01 demonstrated a partial response (defined as a 30% or greater decrease in the size of the tumor) at the eight-month follow-up visit and continued w
Provides Enrollment Update for Phase 1 Study in Late-Stage Non-small Cell Lung Cancer Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable efficacy results from the 12-month follow-up visit for the first patient and the two-month follow-up visit for the seventh patient enrolled in its Deltacel-01 Phase 1 clinical trial, and provides an enrollment update. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic or locally-advanced non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. At the 12-month post-treatment follow-up vi
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable ongoing efficacy results from the eight-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical trial, and provides additional updates on the first and seventh patients. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. 8-Month Follow-Up for Patient #4: Partial Response with Tumor Reduction of 32% Preliminary results from the eight-month follow-up visit for the fourth patient enro
SEC declines to impose civil penalties in light of the Company's self-reporting, prompt remediation and cooperation Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") today announced that it has entered into a settlement agreement with the U.S. Securities and Exchange Commission (the "SEC"), resolving the previously disclosed SEC investigation arising from the non-disclosure by Kiromic's prior executive management of the clinical holds placed on the investigational new drug ("IND") applications the Company filed with the U.S. Food and Drug Administration (the "FDA") in May 2021. The IND applications pertained to ALEXIS-PRO-1 (Procel™) and ALEXIS-ISO-1 (Isocel™). In light of
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable ongoing efficacy results from follow-up visits for Patient 4 and Patient 6 in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. At the six-month follow-up visit, Patient 4 maintained stable disease with a 5.3% reduction in tumor size compared to the pre-treatment size. At the two-month follow-up visit, Patient 6 demonstrated stable disease with no new lesions detected and no si
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports good safety and favorable ongoing efficacy results from the 10-month follow-up visit of the first patient treated in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. In this patient, the tumor size was reduced by approximately 27% compared with the pre-treatment size, and no new sites of disease were identified. As a result, the progression-free survival (PFS) has reached 10 months with
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces that the University of Arizona Cancer Center (UACC) has been activated as the fifth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. The UACC is one of the 57 NCI-Designated Comprehensive Cancer Centers in the U.S. Dr. Ricklie Ann Julian, Assistant Professor of Medicine at UACC, will serve as Principal Investigator at the site. "We are delighted to partner with UACC, expanding our Deltace
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announced today that the Deltacel-01 Safety Monitoring Committee (SMC) has unanimously voted in favor of proceeding with the expansion phase of the Deltacel-01 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. This recommendation by the SMC follows a favorable review of safety data from the first two cohorts, including recent results from the 40-day follow-up visit of the sixth patient in Deltacel-01, which demonstrate
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy. The designation was awarded for KB-GDT-01 in combination with low-dose radiation therapy for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have progressed on at least two lines of standard of care therapy including platinum-based chemotherapy, immune checkpoint inhibitors and targeted therapy to improve progression-free survival and overall survival. Deltacel is currently being evaluated in the Delta
On track to initiate Part 2 in September Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports interim results near the completion of Part 1 of its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. Based on data from the five patients evaluated for Progression-Free Survival (PFS) in the long-term follow-up, Kiromic has registered a PFS ranging from 2 to 8 months, with an average of 4.8 months. No dose limiting toxicities (DLTs) have been r
Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the appointment of Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately. Dr. Mirandola has served as the Company's Vice President of Research & Development and Clinical Translation since September 2021. His previous role was Head of Clinical Translation from 2020 to 2021, having joined the Company in 2016 as Executive Director of Research and Development (R&D). "We are delighted to name
– Frank Tirelli Will Serve as Chair of Kiromic's Audit Committee – – Dr. Reeves Brings Deep Biopharmaceutical, Regulatory, and Clinical Expertise to Board Role – Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today announces the appointment of two outside directors to the Company's Board of Directors: Frank Tirelli and Karen Reeves, M.D. Frank Tirelli was appointed to the Company's Board effective on January 28,
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP) — Expansion of in-house cGMP manufacturing facility to provide support to the Company's clinical trials. Therapeutic doses expected to be ready for first in-human dosing in 3Q-2021. — Mr. Ignacio Núñez, a 20-year industry veteran in global operations and manufacturing, is joining the Kiromic team to take the company to the next level and to scale up cGMP manufacturing capabilities internally. Kiromic is an immuno-oncology company using Artificial Intelligence (AI) to identify critical markers in solid tumors to develop Allogeneic CAR-T cell therapy. Kiromic’s CAR-T technology addresses critical efficacy and safet
Recent Corporate Highlights Include: New Leadership Appointed at the Company, Board of Director Level Completed Studies to Further Optimize Potency and Validity of the ALEXIS Gamma Delta T (GDT) Cell Platform Progressed a Master Cell Bank Strategy for Retro-viral Vector (RVV) Production Enhanced Kiromic's Diamond AI™ Mediated Pooled Donor Gamma Delta T Cell Banking Technology Expansion and Redesign of In-house cGMP Manufacturing Facility DIAMOND®AI 2.0 New Component NOEMI (NeurO Evolutive) Machine Learning Enabled Antibody Design) Designed to Dramatically Reduce Time and Cost of CAR-T Cell Therapy Development Cash Position $15,123,100 as of March 31, 2022 Kiromic BioPh
Highlights Include Company's Progress in the Following Areas: Advances in the Research, Development, and Manufacturing Processes of the ALEXIS Gamma Delta T cell Platform Key Hires in Research & Development, Clinical Translational Medicine and Clinical Trial Preparation Completion of Approximately 90% of In-house cGMP Facility Expansion and Redesign Launch of DIAMOND® Artificial Intelligence (AI) 2.0 Platform for Identification and Selection of Immunotherapy Targets, which Now Includes Nearly Two Billion Data Points Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artific
Kiromic Biopharma, Inc. (NASDAQ:KRBP), a pioneer in immuno oncology cellular therapy in solid tumors, is pleased to announce it has completed the acquisition of InSilico Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005822/en/http://bioinformatics.mdanderson.org/main/SpliceSeq:Overview (Graphic: Business Wire)">SpliceSeq, http://bioinformatics.mdanderson.org/main/SpliceSeq:Overview (Graphic: Business Wire) InSilico Solutions is a world-class bio-informatics and artificial intelligence innovator with a long standing collaborative relationship with its clients at MD Anderson Cancer Center, Johns Hopkins School of